You are using an outdated browser. If you would like to use our website, please use Chrome, Firefox, Safari or other browser
By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement.
These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.
These cookies enable the provision of advanced functionalities and are used for personalization. The cookies are set in particular in response to your actions and depend on your specific service requests (e.g., setting the language).
These cookies may be set to learn more about your interests and show you relevant ads on other websites. These cookies work by uniquely identifying your browser and device. By integrating these cookies, we aim to learn more about your interests and your surfing behavior and to be able to place our advertising in a targeted manner.
Publication of Merck KGaA, Darmstadt, Germany.
In the United States and Canada the subsidiaries of
Merck KGaA, Darmstadt, Germany operate under the umbrella brand EMD.
I am passionate about immunology and find it incredibly rewarding to search for mechanisms that can significantly impact patient’s health and ultimately survival in multiple disease indications. Over the past 6 years at EMD Serono, I’ve had the privilege to lead a diverse team of dedicated scientists who together work to develop a pipeline of novel therapeutics, from concepts through early clinical support, and explore new modalities to impact the lives of patients with cancer.
Filippos joined EMD Serono from Massachusetts General Hospital, where he worked on immunoregulatory networks in HIV and Tuberculosis. He is leading the T cell strategy for the T & NK Cell Innovation cluster, a group of scientists and project teams. Driven by his curious scientific mind and passion about Immunology, Filippos strives to combine new technologies & novel modalities to push the frontiers of scientific knowledge in order to harness the ability of the immune system to fight cancer.
Armine developed deep oncology expertise and a passion for modulating tumor immune cell function through her previous positions. She joined EMD Serono for the unique opportunity to pursue the discovery of immuno-oncology therapies in both small molecule and antibody-based modalities. She enjoys working with experts across various functions in efforts to discover novel therapeutics for patients with cancer.
Meet the Translational Biomarker Research Team
Whether in pharma or biotech, I have always been enthusiastic about translating discoveries in cancer biology into new therapies for patients. In Oncology and Immuno-Oncology Research I have had the opportunity to pursue this passion since joining in 2008. My current role is to lead an international team working to answer key biomarker and translational research questions.
Marat has led collaborations that have entered clinical development & is supporting projects to select and validate potential biomarkers of drug response, to better define molecular profiles of drug-sensitive tumors, & to leverage insights from clinical studies for development of new therapeutic concepts. Marat enjoys working at the interface of immunology, oncology, pharmacology, drug discovery, and early clinical development in hopes of bringing new treatment options to cancer patients.
Tsz-Lun joined EMD Serono after years as an investigator focusing on tumor microenvironment research at a comprehensive cancer center. Since early 2021 his team has supported the translational and biomarker research of the oncology and immuno-oncology pipeline. What he loves about the company is that he is always surrounded by collaborative colleagues with strong and diverse scientific backgrounds, as well as the opportunities and support he received in professional growth and development.
Audrey joined EMD Serono in 2018 as a postdoctoral scientist studying DNA damage response. Now she is a scientist with the Translational Biomarker Research group providing in vitro support for DNA damage response inhibitors in early phase clinical trials. She loves working with a wonderful group of friendly and insightful colleagues, and the opportunity to observe how scientific experiments in the lab can impact clinical trial design and ultimately patient care.
Meet the In vivo Pharmacology Team
Helping to identify drugs which make a difference to patients is what brought me to the organization 20 years ago. Since then, I experienced how gratifying it is to contribute to the progress of cancer drug discovery projects—seeing how great ideas can turn into drugs that inhibit tumor growth. Today, I feel really privileged to be part of this great team of scientists who are supporting our oncology projects with state-of-the art in vivo pharmacology & who help to bring our drugs to patients.
While at EMD Serono, Tim has worked in various disease areas including neuroscience, inflammation, and oncology. During this time, he has contributed to developing a number of molecules in a preclinical setting that have then gone on to become new treatments for patients. As part of the In vivo Pharmacology team within TIP OIO, Tim participates in a variety of projects dedicated to bringing the best medicines to cancer patients.
Since joining EMD Serono in 2020 from academia, Farzana has been responsible for carrying out different in vivo oncology studies, such as MTD, PK/PD, and biomarker study for validation of novel oncology compounds and ensuring the efficacy and safety of anti-cancer effects of a new drug candidate before going to clinical trial. She is proud to be a member of the TIP Oncology IVP group and utilize my scientific and technical expertise to support mission in bringing new drugs to patients.
Work With Us
Start your journey of discovery with our company
Working with us goes far beyond just having a job to make ends meet. Fueled by purpose and rewarded by personal fulfillment, we offer more than just standard career opportunities.